OncoMate MSI Dx Analysis System
Promega Corporation · Decision date Sep 15, 2026
What did the FDA approve?
The FDA database entry records an approval decision dated September 15, 2026, for the OncoMate® MSI Dx Analysis System from Promega Corporation. The device is classified as a nucleic acid based assay for microsatellite instability under product code SFL and specialty Medical Genetics. The statement describes a qualitative multiplex PCR test that detects mononucleotide deletions in five microsatellite loci (BAT-25, BAT-26, NR-21, NR-24 and MONO-27) using DNA from FFPE solid tumor tissue, with a matched normal specimen from the same individual obtained from FFPE tissue or whole blood.
The system is specified for use with the Applied Biosystems® 3500 Dx Genetic Analyzer and OncoMate® MSI Dx Analysis Software. The statement reports the intended use as a companion diagnostic to identify MSI-H patients with advanced solid tumor cancers eligible for treatment with KEYTRUDA® in accordance with the approved therapeutic product labeling. The entry does not include supplement type or supplement reason fields, so no information about a changed item or relationship to a prior PMA is present in the record.
FDA approval order statement
Approval for the OncoMate MSI Dx Analysis System. The OncoMate MSI Dx Analysis System is a qualitative multiplex polymerase chain reaction (PCR) test intended to detect the deletion of mononucleotides in five microsatellite loci (BAT-25, BAT-26, NR-21, NR-24 and MONO-27) using DNA obtained from formalin-fixed, paraffin-embedded (FFPE) solid tumor tissue. The assay requires DNA from a matched normal specimen of the same individual, which may be obtained from FFPE tissue or whole blood. The OncoMate MSI Dx Analysis System is for use with the Applied Biosystems 3500 Dx Genetic Analyzer and OncoMate MSI Dx Analysis Software.The OncoMate MSI Dx Analysis System is intended for use as a companion diagnostic to identify MSI-H patients with advanced solid tumor cancers eligible for treatment with KEYTRUDA in accordance with the approved therapeutic product labeling.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Medical Genetics
- Decision date
- Sep 15, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P250046
- Regulatory pathway
- Premarket approval application
- Applicant
- Promega Corporation
- Product code
- SFL
- Decision code
- APPR
- Decision date
- Sep 15, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Nucleic Acid Based Assay, Microsatellite Instability.
- Applicant
- Promega Corporation
- Product code
- SFL
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P250046 received
Application receipt date recorded by FDA.
P250046 · FDA decision
APPR
Timeline entries are records held by MedtechLedger for P250046. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Promega Corporation
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 2800 Woods Hollow Rd., Madison, WI, 53711
Sources and methodology
- Original FDA record: P250046
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records